Stockreport

FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease

FibroGen, Inc  (FGEN) 
Last fibrogen, inc earnings: 3/2 04:01 pm Check Earnings Report
PDF Roxadustat cardiovascular safety comparable to placebo in non-dialysis dependent (NDD) patients, as assessed by Major Adverse Cardiovascular Events (MACE) and MACE+ [Read more]